window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 21, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

monoclonal antibodies

  • Biotech & Pharma Business,Drug Discovery & Development,Manufacturing & Supply Chain

    Lonza expands DNA-to-IND offering to accelerate biologics development timelines

    Lonza has expanded its integrated DNA-to-IND biologics development offering, introducing [...]

    June 8, 2026
  • Advanced Therapies,Biotech & Pharma Business,Manufacturing & Supply Chain,Therapeutic Areas

    Evotec unit secures BARDA deal to optimise Ebola antibody manufacturing

    Just – Evotec Biologics has been selected by BARDA to [...]

    May 5, 2026
  • Advanced Therapies,Drug Delivery & Formulation,Medical devices,Opinion & Events,Pharmaceuticals and therapeutics

    Datwyler, LTS Device Technologies, and Stevanato Group collaborate on large-volume self-administration solutions

    Datwyler, LTS Device Technologies, and Stevanato Group have launched a [...]

    May 5, 2026
  • Advanced Therapies,Drug Discovery & Development,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    Merck opens climate-neutral €150 million filter manufacturing facility in Ireland

    Merck has inaugurated its first climate-neutral manufacturing facility in Ireland, [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Manufacturing & Supply Chain,Therapeutic Areas

    KBI Biopharma and Infinimmune partner on antibody manufacturing for atopic dermatitis programme

    KBI Biopharma has entered a collaboration with Infinimmune to support [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Manufacturing & Supply Chain

    Symbiosis completes 1,000th batch of sterile injectable drug product

    Contract manufacturer Symbiosis Pharmaceutical Services has announced the completion of [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development

    Kling Bio and Sanofi collaborate to accelerate discovery of next-generation antiviral antibodies

    Biotech company Kling Bio has announced a new collaboration with [...]

    May 5, 2026
  • Advanced Therapies,Drug Discovery & Development,Therapeutic Areas

    Why immunotherapy sometimes fails: Study reveals unintended effects of antibody design

    A new study from researchers in Japan has uncovered a [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Delivery & Formulation,Opinion & Events,Therapeutic Areas

    New research partnership targets $1 malaria prevention shot using next-gen biologics

    Eyam Health, a Canadian biotech, teams with Medicines for Malaria [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Digital & Data

    FDA shifts drug testing paradigm with plan to replace animal studies in monoclonal antibody development

    Regulators back AI and organ-on-a-chip technologies to modernize safety evaluation [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Adneuris licenses Phase 3 pain therapy cebranopadol to Conba for Greater China
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics
  • Latent Labs opens lab-validated AI drug design platform to researchers worldwide
    Categories: Digital & Data, Drug Discovery & Development, Research & Development
  • PET imaging reveals widespread synaptic loss in schizophrenia
    Categories: Clinical & Regulatory, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top